Pages

Showing posts with label Pharmacy Benefit Plan. Show all posts
Showing posts with label Pharmacy Benefit Plan. Show all posts

Monday, October 26, 2015

Pharmacy Benefit Actuarial Services At PBIRx

PBIRx®
Intelligent Solutions in Pharmacy Benefits
612 Wheelers Farms Road, Milford, CT 06461
(888) 797-2479

If you are an entity that provides pharmacy benefits to its employees or members, then we know your primary concern is likely taking care of those who are currently still active in your place of work. But, if you also offer pharmacy benefits to employees who are retired, then it is important to be aware of the aid you may be eligible to receive from the government.

Pharmacy benefit actuarial services by PBIRx

The Retiree Drug Subsidy Program is an opportunity available through Medicare that allows providing entities to continue offering eligible retirees employer sponsored coverage similar to what they received as an active employee. According to the Centers for Medicare and Medicaid Services, "it is generally considered the easiest and most straightforward of the available options, and can often be implemented with little or no benefit design changes to current coverage." That means that those who qualify are likely to be able to receive the same pharmaceutical services they once did even though they are no longer in a position of employment.


To be eligible for the reimbursement (as of January 1, 2006, the government provides a 28% drug subsidy for qualified plans), the Pharmacy Benefit Plan must be equal to or better than the Medicare Part D plan. Furthermore, it is required that an evaluation is completed and signed by a certified actuary, and an application must be submitted to the RDS program 90 days before the plan becomes effective.

How We Help

Here at PBIRx, we have dedicated a division within our company, Pharmacy Benefit Actuarial Services (PBAS), which handles the entire application process for clients seeking the Retiree Drug Subsidy. We have a team of actuaries who possess the certifications needed that can guide you through each of the necessary steps in order to determine your eligibility and ultimately, to receive the subsidy if approved. Below is just some of what we will do to get started:
  • Provide a courtesy review of date including estimated subsidy amount and estimated PBAS services fee.
  • Determine if your plan is eligible.
  • Determine if a modification of the plan will make you eligible if you are not already eligible.
  • Communicate all employer paperwork deadlines required by the government.
  • Develop and participate in a communication strategy for your Medicare eligible employees.


To find out if you are eligible and move forward with the process, we encourage you to give us a call and set up an appointment for your FREE consultation!


For more information, please visit us at www.pbirx.com or contact us at (888) 797-2479.

Tuesday, July 7, 2015

Orkambi Officially Receives FDA Approval

PBIRx®
Intelligent Solutions in Pharmacy Benefits
612 Wheelers Farms Road, Milford, CT 06461
(888) 797-2479

Last month, PBIRx introduced our readers to a new drug known as Orkambi, that was expected to receive FDA approval in early July. Today, we are following up to share the news that the approval has officially gone through!
Orkambi receives FDA approval
As explained by the FDA, this drug was designed to treat cystic fibrosis in individuals that have two copies of a specific mutation. The mutation, known as the F508del mutation, "causes the production of an abnormal protein that disrupts how water and chloride are transported in the body." As of now, this drug will solely be used to treat the disease in patients who are 12 years of age or older, who have two copies of the specific genetic mutation which the drug treats. That represents 28% of cystic fibrosis patients.

Upon hitting the market, Orkambi is expected to cost $259,000 per patient, according to the Wall Street Journal. It's manufacturer, Vertex Pharmaceuticals, anticipates that the drug will be available rather quickly.

Things To Remember:
  • Orkambi is taken orally twice a day. 
  • The drug is a combination of Kalydeco (ivacaftor) and lumacaftor.
  • The effectiveness of Orkambi has not been proven in Cystic Fibrosis patients that do not have two copies the F508del mutation.
  • Side effects of Orkambi include, but are not limited to, shortness of breath, nausea, rash and upper respiratory tract infections.
For more information about Orkambi, please click here.

Here at PBIRx, we realize that the approval of this new drug could affect many pharmacy benefit plans. That's why our team is working closely on analyzing its impact and developing solutions for each of our many clients.

To learn how your pharmacy benefit plan may be affected, please give us a call at 1 (888) Rx-PBIRx (797-2479).